Neurology
News
BACE-1 inhibition worsens cognition in patients with prodromal Alzheimer’s disease
Inhibiting the APP-cleaving enzyme decreased the toxic amyloid species, but it also worsened cognition and caused a variety of concerning adverse...
FDA/CDC
FDA to expand opioid labeling with instructions on proper tapering
The label changes are intended to be used when both the clinician and patient have agreed to reduce the opioid dosage.
Cases That Test Your Skills
The angry disciple
Mr. J, age 54, is agitated, disruptive, and claims to be the ‘son of Jesus Christ.’ He left his job and family to travel to the Middle East to be...
Feature
Report calls for focus on ‘subpopulations’ to fight opioid epidemic
“Methadone, buprenorphine, and extended-release naltrexone ... save lives” but most people with OUD get no treatment, new report says.
Latest News
Biogen, Eisai discontinue aducanumab Alzheimer’s trials
All trials – the phase 3 ENGAGE and EMERGE trials, phase 2 EVOLVE safety study, and the long-term extension of the phase 1b PRIME study – have...
Commentary
Boosting Alzheimer’s trial participation via Medicare Advantage ‘memory fitness programs’
Dr. Richard J. Caselli comments on a new initiative from the Global Alzheimer’s Platform (GAP) Foundation.
From the Journals
In utero infections raise risk for autism
From the Journals
Total plasma tau correlates with dementia onset, Alzheimer’s disease
From the Editor
Psychiatry and neurology: Sister neuroscience specialties with different approaches to the brain
Every patient with a brain or mind disorder should receive both neurologic and psychiatric evaluation and treatment.
From the Journals
In California, opioids most often prescribed in low-income, mostly white areas
Opioid-related overdose deaths are highest in low-income white areas.
News from the FDA/CDC
FDA issues warnings to companies selling illegal Alzheimer’s treatments
The FDA targeted more than 58 products.